Key pathophysiologic mechanisms include: Mucosal barrier dysfunction: Impaired epithelial tight junctions allow bacterial translocation, triggering innate immune activation T-helper cell dysregulation: Predominantly Th1 and Th17 pathways drive chronic inflammation via TNF-, IL-12, IL-23 the basis for biologic therapy targets Transmural inflammation: Unlike UC (mucosal only), CD involves all layers: mucosa submucosa muscularis propria serosa Granuloma formation: Non-caseating granulomas are pathognomonic but present in only ~3050% of biopsies Fibrosis and stricture: Chronic inflammation activates myofibroblasts collagen deposition luminal narrowing obstructive symptoms Fistula formation: Transmural ulcers penetrate serosa form sinus tracts connect to adjacent bowel, bladder, vagina, or skin 7
Amino acids, peptides and trace elements that make up the drug, show synergism of action, thereby enhancing the action of each other.
Today, its used to treat problems such as repetitive neck spasms, eye twitching, and overactive bladder
Even with excellent clinical trial safety data, individual responses may vary
Healthcare providers typically use this rapid delivery method for immediate clinical interventions or specific pain management protocols
